Epigenetics in Precision Medicine

· Translational Epigenetics 30 巻 · Elsevier
電子書籍
614
ページ
利用可能
評価とレビューは確認済みではありません 詳細

この電子書籍について

In recent years, knowledge of epigenetic mechanisms underlying disease onset and progression has proven crucial for the development of novel early diagnosis and prognosis biomarkers for patient stratification and precision medicine. Epigenetics in Precision Medicine, a new volume in the Translational Epigenetics series, provides a thorough discussion and overview of current developments in clinical epigenetics with special emphasis on epigenetic biomarkers that can be used for clinical diagnosis, prognosis, patient stratification, and treatment monitoring. Disease types discussed include cancer, metabolic disorders, neurodegenerative diseases, bone disease, and immune-related disorders. The book examines the challenges of advancing epigenetics research and translating findings to the clinic and drug discovery in each of these areas, as well as current solutions; chapter authors discuss how to leverage epigenomic technologies, applications, and tools, such as next-generation sequencing, to discover new epigenetic biomarkers in disease and drug studies. Epigenetics in Precision Medicine focuses on complex epigenetic mechanisms in several pathologies, and explores how epigenetics can power the advance of precision medicine, not only by improving in vitro diagnostic and prognostic tools, but by providing new therapeutic approaches to treat human disease. - Provides a thorough grounding in epigenetics-driven precision medicine, with emphasis on developing and implementing early diagnosis and prognosis biomarkers, and supporting patient stratification - Empowers researchers and clinicians to incorporate epigenetics in new disease research, drug discovery, and clinical practice - Features chapter contributions from international leaders in the field

著者について

Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.

この電子書籍を評価する

ご感想をお聞かせください。

読書情報

スマートフォンとタブレット
AndroidiPad / iPhone 用の Google Play ブックス アプリをインストールしてください。このアプリがアカウントと自動的に同期するため、どこでもオンラインやオフラインで読むことができます。
ノートパソコンとデスクトップ パソコン
Google Play で購入したオーディブックは、パソコンのウェブブラウザで再生できます。
電子書籍リーダーなどのデバイス
Kobo 電子書籍リーダーなどの E Ink デバイスで読むには、ファイルをダウンロードしてデバイスに転送する必要があります。サポートされている電子書籍リーダーにファイルを転送する方法について詳しくは、ヘルプセンターをご覧ください。